On April 23, 2025, Salarius Pharmaceuticals, Inc. was notified by Nasdaq of non-compliance with listing rules due to its stock price falling below $1 and lacking sufficient equity, threatening delisting on May 2, 2025. The company plans to appeal this decision and aims to regain compliance through a merger with Decoy Therapeutics Inc.